Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of “Moderate Buy” by Analysts

Alto Neuroscience, Inc. (NYSE:ANRO) has received an average rating of “Moderate Buy” from the eight ratings firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $26.3333.

Several research firms have recently commented on ANRO. Wall Street Zen upgraded shares of Alto Neuroscience from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Alto Neuroscience in a research note on Monday, December 29th. Jefferies Financial Group upped their target price on Alto Neuroscience from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, November 12th. Robert W. Baird lifted their price target on Alto Neuroscience from $16.00 to $22.00 and gave the company an “outperform” rating in a report on Thursday, November 13th. Finally, BTIG Research initiated coverage on Alto Neuroscience in a research report on Monday, November 17th. They set a “buy” rating and a $27.00 price objective on the stock.

Institutional Investors Weigh In On Alto Neuroscience

Several institutional investors have recently bought and sold shares of the company. Torren Management LLC acquired a new position in shares of Alto Neuroscience during the fourth quarter worth $62,000. Bank of Montreal Can purchased a new position in Alto Neuroscience during the 2nd quarter worth $25,000. Ground Swell Capital LLC acquired a new position in Alto Neuroscience during the 2nd quarter valued at about $27,000. Vanguard Personalized Indexing Management LLC purchased a new stake in Alto Neuroscience in the second quarter valued at about $33,000. Finally, AlphaCore Capital LLC raised its stake in Alto Neuroscience by 100.0% in the fourth quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock valued at $356,000 after buying an additional 10,000 shares during the last quarter.

Alto Neuroscience Stock Up 8.9%

Shares of NYSE ANRO opened at $15.37 on Monday. Alto Neuroscience has a 52-week low of $1.60 and a 52-week high of $20.91. The firm has a market capitalization of $477.61 million, a price-to-earnings ratio of -6.71 and a beta of 2.79. The stock has a 50 day moving average price of $16.43 and a 200 day moving average price of $10.24. The company has a debt-to-equity ratio of 0.20, a quick ratio of 15.42 and a current ratio of 15.42.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Wednesday, November 12th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.14. Sell-side analysts expect that Alto Neuroscience will post -2.54 earnings per share for the current year.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.